
News|Articles|October 3, 2026
Emerging Research Insights and New Advances in Neuroradiology
Author(s)Diagnostic Imaging Staff
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Will a new positron emission tomography (PET) agent be a game changer for glioma imaging? Are patients with diabetes and lower bone mineral density (BMD) on chest CT more susceptible to faster accumulation of white matter hyperintensity (WMH)? Can newly FDA-cleared software facilitate improved quality of amyloid PET imaging via structural MRI?
Related to this article

Catch up on the most-well viewed radiology content in September 2026.

In a recent interview, Shadpour Demehri, MD, discussed new research examining connections between deep learning assessment of bone mineral density on chest CT, brain MRI data and the potential for enhanced risk stratification in patients with diabetes.

In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.

Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.

Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.
Advertisement
Advertisement



